EYPT Q3 2022 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+10.5% YoY

Gross Profit

$9M86.0% margin

Operating Income

-$18M-183.8% margin

Net Income

-$18M-184.0% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-13.4%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$220M

Total Liabilities

$84M

Stockholders' Equity

$136M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$9M	+10.5%
Gross Profit	$9M	$7M	+19.0%
Operating Income	-$18M	-$15M	-20.1%
Net Income	-$18M	-$17M	-10.3%

Revenue Segments

Y U T I Q Product

$7M75%

D E X Y C U Product

$2M25%